Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Prostatic Neoplasms × capivasertib × Clear all

Phase

Phase 3 2 Phase 1 2 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Leukemia 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Recurrence 1 Prostatic Neoplasms 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasms 1 Melanoma 1 Lymphoma 1 Estrogen Receptor Positive Breast Cancer 1

Interventions

Docetaxel 27 Prednisone 22 enzalutamide 15 pembrolizumab 10 Abiraterone Acetate 9 gallium 68 PSMA-11 8 Radiotherapy 8 Pluvicto 8 Leuprolide 7 Nivolumab 6 Magnetic Resonance Spectroscopy 6 Estramustine 5 Biopsy 5 orteronel 4 olaparib 4 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 4 Specimen Handling 4 Radiotherapy, Intensity-Modulated 4 Granulocyte-Macrophage Colony-Stimulating Factor 4 Cyclophosphamide 4 Carboplatin 4 tremelimumab 3 durvalumab 3 darolutamide 3 cemiplimab 3 cabazitaxel 3 bicalutamide 3 avelumab 3 abiraterone 3 Radiosurgery 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02121639 2022-05-05

ProCAID

University Hospital Southampton NHS Foundation Trust

Phase 1/2 Completed

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡